Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with diabetic macular edema treated with ranibizumab

Table 3 Univariate and multivariate linear regression analyses for predicting BCVA changes in DME patients treated with IVR

	B	SE	β	T	P value
Univariate linear regression
Baseline BCVA	−0.105	0.033	−0.319	− 3.177	0.002
Baseline CRT	0.010	0.004	0.280	2.753	0.007
Lymphocytes	3.049	0.812	0.370	3.756	<0.001
Neutrophils	−0.983	0.237	−0.403	−4.151	<0.001
NLR	−1.986	0.276	−0.607	−7.202	<0.001
MLR	−15.471	3.929	−0.385	−3.938	<0.001
PLR	−0.035	0.009	−0.387	− 3.955	<0.001
Multivariate linear regression
Baseline BCVA	−0.081	0.027	−0.246	−3.027	0.003
NLR	−1.884	0.266	−0.576	−7.079	<0.001

SE standard error, BCVA best-corrected visual acuity, CRT central retinal thickness, NLR neutrophil-to-lymphocyte ratio, MLR monocyte-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio

ISSN: 1471-2415